A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01313364|
Recruitment Status : Terminated (The objective of the study has been achieved with fewer subjects than planned.)
First Posted : March 11, 2011
Last Update Posted : August 12, 2011
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Device: 25G x 1" Needle Autoinjector||Phase 1|
This is a single-arm, single-center study in healthy volunteers. The study is designed to evaluate the safe use of the single-use autoinjector with a 25G × 1" needle in subjects of varying body mass indices (BMIs). Because this is a safety study of the injector, the injections contain Avonex excipients only; no active IFNβ-1a will be administered.
During the study, each subject will self-administer 4 IM injections using single-use autoinjectors.
Subjects will self-administer the first 2 injections (1 in each thigh) and then repeat the process approximately 60 to 90 minutes later. A Trainer/Observer will prepare the autoinjector for each injection, monitor each injection, and assess the subject for AEs during the injection process and up to the time of discharge from the unit. The Trainer/Observer will also visually inspect the needle pre- and post-injection and record their findings. The Investigator or designee (physician or nurse) will assess injection sites for erythema, induration, tenderness, or warmth.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle|
|Study Start Date :||March 2011|
|Primary Completion Date :||April 2011|
|Study Completion Date :||April 2011|
Experimental: All subjects to self-administer 4 IM injections
Subjects will be recruited and stratified into BMI groups: <18.5 kg/m2, 18.5 to 24.9 kg/m2, 25 to 29.99 kg/m2, and >30 kg/m2 all with 20 subjects. To maintain a balance between sexes that is representative of the MS population, approximately 50 to 70% of subjects within each BMI group should be female.
Device: 25G x 1" Needle Autoinjector
All subjects will self-administer 4 IM injections using single-use autoinjectors.
- Incidence of treatment-emergent AEs reported when using the single-use autoinjector with a 25G x 1" needle [ Time Frame: 24 hours ]
- Incidence (post-injection) of clinician-assessed injection site erythema, induration, tenderness, or warmth [ Time Frame: 24 hours ]
- Incidence of abnormal post-injection needle observations [ Time Frame: 24 hours ]
- Incidence of AEs associated with abnormal post-injection needle observations [ Time Frame: 24 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01313364
|Toronto, Ontario, Canada|